1. Home
  2. WVE vs HTFL Comparison

WVE vs HTFL Comparison

Compare WVE & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$5.68

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

HTFL

Heartflow Inc.

HOLD

Current Price

$30.11

Market Cap

2.5B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
WVE
HTFL
Founded
2012
2007
Country
Singapore
United States
Employees
317
843
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
2.5B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
WVE
HTFL
Price
$5.68
$30.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
16
5
Target Price
$29.81
$38.20
AVG Volume (30 Days)
3.9M
1.1M
Earning Date
04-28-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,704,000.00
N/A
Revenue This Year
N/A
$27.66
Revenue Next Year
$85.67
$23.55
P/E Ratio
N/A
N/A
Revenue Growth
149.43
N/A
52 Week Low
$5.02
$20.13
52 Week High
$21.73
$41.22

Technical Indicators

Market Signals
Indicator
WVE
HTFL
Relative Strength Index (RSI) 35.24 52.83
Support Level $5.02 $28.37
Resistance Level $7.65 $32.69
Average True Range (ATR) 0.32 1.87
MACD 0.00 -0.09
Stochastic Oscillator 10.14 53.55

Price Performance

Historical Comparison
WVE
HTFL

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About HTFL Heartflow Inc.

HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.

Share on Social Networks: